FDA Drug Recalls

Recalls / Class III

Class IIID-0330-2021

Product

Distributed by: DocRx, Methylprednisolone Tablets, USP 4 mg, Rx, 21 Count Blister, NDC: 69306-004-21, Relabeled by: Enovachem Pharmaceuticals 379 Van Ness Ave. Suite 1403-1406, Torrance, CA 90501, Manufactured by: Jubilant Cadista Pharmaceuticals Inc. Source NDC: 59746-001-03, DocRx, Mobile, AL 36608

Brand name
Methylprednisolone
Generic name
Methylprednisolone
Active ingredient
Methylprednisolone
Route
Oral
NDCs
59746-001, 59746-002, 59746-003, 59746-015
FDA application
ANDA040189
Affected lot / code info
Lot #: 20K0043P, Exp. 8/31/2022; 20L0026P, Exp. 9/30/2022

Why it was recalled

Labeling: Illegible label: Manufacturer received complaint of mis-alignment print of the printed dosing instructions on the blister card.

Recalling firm

Firm
Asclemed USA Inc. dba Enovachem Pharmaceuticals
Manufacturer
Jubilant Cadista Pharmaceuticals Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
379 Van Ness Ave Ste 1403, N/A, Torrance, California 90501-7211

Distribution

Quantity
N/A
Distribution pattern
Distributed to three physicians in the following states: CA, LA (Enovachem). DocRx distributed recalled product to one Distributor located in AL.

Timeline

Recall initiated
2021-03-19
FDA classified
2021-04-12
Posted by FDA
2021-04-21
Status
Ongoing

Source: openFDA Drug Enforcement endpoint. Recall record D-0330-2021. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class III recall: Methylprednisolone · FDA Drug Recalls